PlasmaGen Biosciences (PlasmaGen), a biopharmaceutical company recently celebrated the official opening of its new production facility for blood plasma-derived protein therapeutics in Kolar, Bengaluru.

PlasmaGen is primarily focused on blood plasma-derived pharmaceutical products for India and emerging markets. The facility will greatly enhance the supply-demand situation for reasonably priced blood-plasma-derived products.

VinodNahar, Founder & Managing Director, PlasmaGen Biosciences said, "PlasmaGen's new facility is the latest example of our investment in the future – which includes advancing our growing capabilities in manufacturing plasma-derived products at scale." He further added, "At this facility, which also houses the largest R&D infrastructure and quality control lab in the blood plasma industry in the country, we aim to produce multiple plasma products like albumin, immunoglobulins, and coagulation factors in our mission to be a trusted and leading Indian biopharmaceutical company, dedicated to improving the health and quality of life of patients."

To efficiently meet the potential domestic demand, the WHO estimates that India needs to process 7 million liters of blood plasma (compared to 1 million liters now).

A huge opportunity exists for Indian manufacturers to successfully meet the demand in emerging markets given that 91 nations are dependent on imported plasma-derived goods.

With the opening of this new facility, PlasmaGen is aiming to increase patient access to blood-plasma-derived products in India and other developing nations. With a process technique that was developed in-house above previously existing technologies, the production facility has the initial capacity to process 5,000 liters of plasma per year, producing higher yields of very high-quality products.

Multiple plasma products, including albumin, immunoglobulins, and coagulation factors, will be produced at the facility. The design includes additional capacity, enabling PlasmaGen to increase the range of its products in the future.